Meet FACE by Galderma

The app provides advanced wrinkle detection as well as the possible results of 19 injectable treatments, which are displayed as dynamic “before and after” images.

Galderma is launching FACE by Galderma, an app that simulates the results of injectable treatments in real time using digital facial assessment.

The technology was unveiled at the International Master Course on Aging Science (IMCAS) World Congress 2023 in Paris. FACE by Galderma will be available in the United States and Brazil in the first half of 2023, with a global roll out across Latin America, Europe, Middle East, Canada and Asia throughout 2023.

The application provides advanced wrinkle detection as well as the possible results of 19 injectable treatments, which are displayed as dynamic “before and after” images.

In a global pilot study, 80% of respondents said the application helped them to understand their treatment options. Meanwhile, 85% stated that they would recommend the application, and 91% said they plan to return to their practitioner to continue their treatment plan.

 “We developed this game-changing solution to support aesthetic practitioners and give patients a visual representation of what they can expect from the procedures included in their treatment plan,” says Gerry Muhle, the head of the Global Business Unit of Asethetics at Galderma, in a news release. “For example, the real-time injectable results feature simulates how a treatment might augment a patient’s lips, cheeks or chin. FACE by Galderma™ offers patients a realistic visual of their results before treatment even begins, supporting them to establish treatment objectives and priorities alongside their practitioner. It gives them the freedom to make their aesthetic goals a reality.”

The assessment is based on Galderma’s Five Facet Assessment that considers skin quality, facial shape, facial symmetry, facial proportions, and contour, as well as animation and emotional expression. Following the assessment, priority areas can be identified, and an individualized treatment plan can be created. 

The technology behind FACE by Galderma was developed in partnership with Crisalix, the worldwide leading reference in 3D, virtual reality and augmented reality aesthetic simulation.

Of the respondents, 80% said the application helped them to understand their treatment options, while 73% agreed that it made them contemplate a procedure they had not previously considered. Meanwhile, 61% stated that they plan to show their “before and after” images to friends. Overall, 85% said they would recommend the application, and 91% said they plan to return to their practitioner to continue their individualized treatment plan.

 “Patients come to my practice for a consultation because they are interested in an aesthetic injectable procedure, often have questions and are apprehensive about how the procedure will turn out and whether it will look natural and address their wrinkles,” says Aleksandra Bielawiec, NP, a nurse injector at the Regency Medical Spa & Hair Clinic in Barrington, Ill. "The advanced technology available via the new FACE by Galderma tool provides my patients with a simulation of their outcome in advance of the procedure, which should help alleviate their concerns and build trust.”

FACE by Galderma features 19 potential injectable results using products from the Galderma portfolio (depending on local indications), enabling patients to see simulated visuals in real time. Treatment options include:

• Neuromodulators, such as DYSPORT, AZZALURE (EU) and ALLUZIENCE (the first ready-to-use liquid botulinum toxin type A, approved in June 2021 for use in Europe (excluding Greece, Lithuania, Estonia, Latvia and Hungary)).
• Biostimulators, including SCULPTRA
• Products from the hyaluronic acid filler range, RESTYLANE and RESTYLANE SKINBOOSTERS

 The tool also enables clinics to store all patient records in one place, including the treatment plan, “before and after” video and images, and appointment schedules. Patients can also access their FACE by Galderma™ account and view their individual patient profile from home.